Recent clinical trial results have elevated Eli Lilly’s Mounjaro, a GLP-1 receptor agonist, demonstrating cardiovascular benefits comparable to established treatments in large-scale diabetes studies. Similarly, researchers at McMaster University identified a novel strategy to stimulate immune responses in liver cancer by metabolically reprogramming the tumor microenvironment through ACLY inhibition, notably engaging B cells. Advances further include characterization of new aldosterone synthase inhibitors like Baxdrostat exhibiting promising blood pressure control and potential to transform resistant hypertension management.